Advancements in molecular biology and immunochemistry have ushered in a new class of precision-targeted immunizations, prominently represented by synthetic and peptide vaccines. These formulations are designed using defined amino acid sequences or chemically synthesized antigens that mimic pathogen epitopes. Their benefits include high specificity, ease of standardization, and reduced risk of adverse immune reactions. Researchers are refining multivalent designs, conjugation techniques, and delivery systems to improve immunogenicity and durability. Their synthetic nature enables rapid adaptation to emerging variants and efficient large-scale production. As global health demands grow more complex, Synthetic and peptide vaccines are proving valuable in addressing infectious diseases, allergies, and cancer immunotherapy—offering a path toward highly tailored and responsive vaccine platforms.
Khursheed Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United Kingdom
Elena Chiappini
University of Florence, Italy
Ayesha Zahid
Griffith University, Australia
Livia Daflon Silva
Federal University of State of Rio de Janeiro, Brazil
Neha Bhandari
Chitkara University, IndiaSubmit your abstract Today
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States